By Catherine Shaffer, BioWorld Today Contributing Writer

A research collaboration between Pfizer Inc. and Biovista Inc. will seek new indications for Pfizer drug candidates in development using a bioinformatics technology platform developed by Biovista. Terms of the agreement include identification of up to three new indications for each drug. Biovista will receive an undisclosed up-front payment and success milestone payments. “Pfizer enjoys a significant leadership in the pharmaceutical industry in terms of wishing to systematically explore new uses of its drugs,” Aris Persidis, president of Biovista, told BioWorld Today.

Read More…